Eric Lefkofsky is a US businessman who is most well-known for his company Groupon. His latest professional venture is Tempus which could revolutionize how we approach cancer treatments and research in the future. Tempus has a goal to create a genomic database of cancer which would allow physicians to specifically target the therapeutic efforts to combat cancer by comparing cancer patient’s DNA from around the world. After discovering that the technology to create such a database was becoming more accessible and that the data was already there, it seemed like a no-brainer to help establish a database that would help physicians analyze this data.Tempus has teamed up with some of the most reputable hospitals to collect data and has already implemented a 20,000-square ft. lab where gene-sequencing will be performed. Once the database is built, Tempus will provide physicians with software to help them analyze data with ease. Tempus isn’t just a company, it could pave the way to miraculous scientific discoveries surrounding one of the most serious conditions plaguing the world today.
About the Entrepreneur and Businessman Eric Lefkofsky
Aside from Tempus and Groupon, Eric Lefkofsky is a founding partner of Lightbank and a co-founder of Uptake Technologies. Prior to his successful career as a serial entrepreneur and businessman in the Chicago area, Eric Lefkofsky attended the University of Michigan and the University of Michigan Law School.
Tempus isn’t the first technological or medical based venture that Eric has teamed up with or facilitated. Eric and his wife Liz established the Lefkofsky Family Foundation in 2006 to help fast track research, programs, and initiatives aimed at improving the quality of life for people at home and around the world. The Lefkofsky’s have also made significant donations to cancer centers, as well as gastric and breast cancer research. If Tempus is as successful as his previous ventures, you can be sure that it is sure to make waves throughout the medical, scientific, and technological communities.
Eric Lefkofsky has used his innovative mind to create companies that have made positive changes in the world. Lefkofsky is a Michigan born man who graduated from the University of Michigan. Lefkofsky has a net worth of about 1.97 billion dollars. He is a person who has used his influence and wealth to help others. Tempus is a company that was created by Eric Lefkofsky. This is a company that was created to help those individuals who are suffering from cancer. The general treatment for cancer is the use of radiation or chemotherapy. These are treatments that are made to help cure certain types of cancers, but each individual is different when it comes to their cancer diagnosis. An individual has a much better chance of getting a cure if they get a medication that is tailored suited to their genetic makeup. Targeted cancer care is the total concept of Tempus.
Tempus works with different hospitals like Penn Hospital and the Mayo Clinic to approach the genomic data of each individual. Their technology uses sequencing to get a better understanding of each patient’s type of cancer. Using Tempus technology, a physician can analyze their patient’s DNA on a molecular level, and they can find a personal treatment for them. This is the only type of medical technology of its kind. Tempus assists doctors in making medical decisions that can treat patients in an effective manner.
Another monumental achievement of Eric Lefkofsky and his wife is the Lefkofsky Family Foundation. This is a foundation that was created to work in tandem with other charities. The Lefkofsky Family Foundation is a foundation that gives to the arts, education, and human rights. This foundation has the goal of helping to improve the quality of life of all human beings. The Lefkofsky Family Foundation is also dedicated to their community. The Lefkofsky family is a family that gives of their funds and their time to promote growth and culture in their local community.
Seattle Genetics is a Bothell, Washington based biotechnological company that creates drugs specifically to kill cancer.
The ACD’s, or antibody drug conjugates are intended to lessen the toxicity in chemotherapy while enhancing anti-tumor therapies. Seattle Genetics was incorporated in 1998. Its flagship product Adcesis is now available in 50 countries.
Dr. Clay Siegall is the company’s board chairman and CEO. He co-founded the company in 1998. Dr. Siegall is responsible for helping Seattle Genetics introduce a new line of cancer treatment drugs that fight tumors. Seattle Genetics has collaborated with a number of pharmaceutical companies including Bayer, Genetech, Benmab and Unem Therapeutics. Seattle Genetics has raised more than $300 million in capital to help with drug studies and exclusive collaboration efforts.
Under the leadership of Dr. Siegall, Seattle Genetics has acquired a number of strategic licenses. Before Seattle Genetics, Dr. Siegall worked for Bristol Meyers Squibb. He also worked at the National Cancer Institute and the National Institutes of Health. Dr. Siegall has an extensive educational background. He graduated from the University of Maryland with a B.S. in Zoology. He then attended George Washington University and received a Ph.D in Genetics.
Dr. Siegall sits on a number of boards including Ultragenics Pharmaceuticals Inc., Aldo Pharmaceuticals and Mirna Theraputics. He is the holder of 15 patents and been published more than 70 times. Dr. Siegall has won numerous awards for excellence including the University of Maryland Alumnus of the Year and the Ernst and Young Entrepreneur of the Year for 2012.